Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML - Interim Results from ALLG CML13 Ascend-CML
David T Yeung(Royal Adelaide Hospital), Timothy P. Hughes(Royal Adelaide Hospital), Nicholas Viiala(Liverpool Hospital), Susan Branford(South Australia Pathology), Rosemary Harrup(University of Tasmania), Naranie Shanmuganathan(South Australia Pathology), Kate Burbury(The University of Melbourne), Carolyn Grove(The University of Western Australia), David M. Ross(Flinders Medical Centre), Cecily Forsyth(Gosford Hospital), Alwyn Bernard D'Souza(Wellington Hospital), John Reynolds(The Alfred Hospital), Andrew Grigg(Austin Health), Jake Shortt(The University of Melbourne), Steven Lane(QIMR Berghofer Medical Research Institute), Agnes S. M. Yong(South Australia Pathology), Mannu Walia(St Vincents Institute of Medical Research), Ilona Cunningham(The University of Sydney), Peter Browett(University of Auckland), Matthew Wright(The University of Western Australia), Robin Filshie(St Vincent's Hospital Melbourne)
Cited by 4
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Targetable Kinase-Activating Lesions in Ph-like Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2014|1.4k
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464